Immunocore Holdings plc Long-Term Debt, Maturity, Remainder of Fiscal Year
Immunocore Holdings plc (IMCR) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $0 as of 2024-09-30, per its 10-Q filed 2024-11-06.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2024-11-06
- 2024-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
- 2024-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
- 2024-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2024-09-30 | $0.00 10-Q · filed 2024-11-06 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-08 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |